Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
50.45
+5.18 (+11.44%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)
October 09, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
October 08, 2023
From
Bristol Myers Squibb
Via
Business Wire
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
October 05, 2023
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
September 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
September 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
September 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
September 14, 2023
From
Bristol Myers Squibb
Via
Business Wire
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
September 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
September 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
September 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 01, 2023
From
Bristol Myers Squibb
Via
Business Wire
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
August 28, 2023
From
Bristol Myers Squibb
Via
Business Wire
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
August 28, 2023
From
Bristol Myers Squibb
Via
Business Wire
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
August 25, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments
August 23, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
August 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
August 21, 2023
From
Bristol Myers Squibb
Via
Business Wire
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
August 16, 2023
From
Bristol Myers Squibb
Via
Business Wire
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
August 11, 2023
Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains
Via
MarketBeat
Exposures
COVID-19
Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts
August 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements
August 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
August 08, 2023
From
Bristol Myers Squibb
Via
Business Wire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
August 01, 2023
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Attractive Large Caps on Sale After Q2 Earnings
July 31, 2023
For investors that like to sift through the underperformers for good values, good factors to identify are market overreaction and healthy long-term outlooks.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Exscientia is the Sniper of the AI Drug Discovery Industry
July 27, 2023
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
July 27, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
July 21, 2023
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.